Marksans Pharma Q2FY27 Revenue Crosses ₹900 Cr; EBITDA Surges 48%
Marksans Pharma reported record Q2FY27 revenue of ₹940 crore, up 30.5% YoY. EBITDA surged 48.3% to ₹214 crore. For H1FY27, revenue reached ₹1,781 crore, and PAT nearly doubled to ₹303 crore. The company ended with a strong cash balance of ₹1,124 crore. An earnings conference call is scheduled for November 5, 2026.
The announcement details record financial results, significant year-on-year growth in revenue and profits, and strong performance in key international markets. This level of positive financial news is expected to have a high impact on investor sentiment and the company's stock.
The company reported record revenues, significant EBITDA growth, and a substantial increase in PAT, indicating strong financial performance. Positive commentary from the MD and robust growth across key markets further support the positive sentiment.
Marksans Pharma Limited announced its unaudited financial results for the quarter and half year ended September 30, 2026. The company achieved a landmark quarter with its strongest-ever performance, with revenue reaching ₹940 crore, a 30.5% year-on-year increase. Adjusted for the acquisition of QliniQ, the revenue growth was a healthy 25%.
EBITDA for the quarter grew by 48.3% to a record ₹214 crore, with margins expanding by 274 basis points to 22.8%. For the first half of FY27 (H1FY27), revenue grew by 32.9% to ₹1,781 crore. EBITDA rose by 74.7% with margins up 574 basis points to 24.0%, and Profit After Tax (PAT) nearly doubled to ₹303 crore, representing over 70% of the full-year FY26 profit.
The growth was broad-based across key markets. The UK & Europe region grew by 64.9% to ₹405 crore in Q2, with the base business growing 48.6% organically, and QliniQ contributing approximately ₹84 crore in H1. Australia & New Zealand grew by 64.0%, and the US & North America region delivered its highest-ever quarterly revenue of ₹421 crore. The company also demonstrated strong cash generation, with H1 operating cash flow reaching ₹322 crore, 4.3 times the previous year, and cash balances closing at ₹1,124 crore. Trailing twelve-month ROCE improved to 24.7%.
Mark Saldanha, Founder, Chairman & Managing Director, expressed confidence in the company's growth trajectory, supported by an expanding global footprint, a robust product pipeline, and a strong net-cash position. The company's focus remains on sustaining profitable organic growth while selectively pursuing strategic acquisitions.
Financial Highlights for Q2FY27 include Operating Revenue of ₹940 crore (up 30.5% YoY), Gross Profit of ₹550 crore (up 33.6% YoY), EBITDA of ₹214 crore (up 48.3% YoY), and PAT of ₹144 crore (up 44.8% YoY). Diluted EPS was ₹3.11.
For H1FY27, Operating Revenue was ₹1,781 crore (up 32.9% YoY), Gross Profit was ₹1,047 crore (up 36.0% YoY), EBITDA was ₹427 crore (up 74.7% YoY), and PAT was ₹303 crore (up 92.5% YoY). Diluted EPS was ₹6.58.
Business-wise performance showed US & North America at ₹421 crore (up 8.7% YoY), UK and Europe at ₹405 crore (up 64.9% YoY), and Australia & New Zealand at ₹101 crore (up 64.0% YoY). The RoW market reported revenues of ₹14 crore (down 47.0% YoY).
An earnings conference call is scheduled for November 5, 2026, at 4:00 pm IST to discuss the financial performance.
What to do with a filing like this
Marksans Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Marksans Pharma Limited. Read the original for the full detail.